Advertisement

The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson’s disease

  • M. B. H. Youdim
  • D. Ben-Shachar
  • P. Riederer
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)

Summary

Recent evidence suggests that iron accumulates in substantia nigra pars compacta of patients with Parkinson’s disease (PD). This finding is compatible with changes in the respiratory chain activity, increase of malondialdehyde concentration (a measure of lipid peroxidation), decrease of enzyme activity of enzymes involved in detoxication of hydrogen peroxide and oxygen radical species, increased MAO-B-activity in this brain area etc. All these data suggest that oxidative stress may play a certain role in the pathobiochemistry of PD. In addition to the description of the neuroprotective mechanism of the MAO-B-inhibitor L-deprenyl a new aspect focuses the role of the endogenous MAO-B substrates “polyamines” which occur both in neurons and glia. A further aspect of this review deals with the role of calcium as cellular toxin. Although of major importance it is not decided yet whether these biochemical changes are of primary or secondary importance to the pathogenesis of PD.

Keywords

Substantia Nigra Ornithine Decarboxylase Brain Iron Oxygen Radical Species High Affinity Binding Site 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anon B (1981) Polyamines as cellular regulators. Med Biol 59 (5-6) Ben-Shachar D, Riederer P, Youdim MBH (1990) The implications of high affinity binding sites for 39Fe on dopamine-melanin and potentiation of iron induced lipid peroxidation for Parkinson’s disease. Eur J Pharmacol (submitted).Google Scholar
  2. Ben-Shachar D, Youdim MBH (1990) Selectivity of melaninized nigrostriatal dopamine neurons to degeneration in Parkinson’s disease may depend on ironmelanin interaction. J Neural Transm [Suppl] 29:251–258.Google Scholar
  3. Birkmayer W, Knoll J, Riederer P, Hars V, Youdim MBH, Marton J (1985) Improvement of life expectancy due to L-deprenyl addition to Madopar treatment in Parkinson’s disease. A long term study. J Neural Transm 64:113–127.Google Scholar
  4. Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) (—)Deprenyl leads to prolongation of L-dopa efficacy in Parkinson’s disease. Mol Probl Pharmacopsychiatry 19:170–176.Google Scholar
  5. Bolkenius FM, Seiler N (1986) Role of polyamines in the development of gabaergic neurons. Int J Dev Neurosci 4:217–224.PubMedCrossRefGoogle Scholar
  6. Boobis AR, Fawthrop DJ, Davies DS (1989) Mechanism of cell death. TIPS 10:275–280.PubMedGoogle Scholar
  7. Braughler JM (1988) Calcium and lipid peroxidation. In: Halliwell B (ed) Oxygen radicals and tissue injury. FASEB, Bethesda, pp 99–106.Google Scholar
  8. Braughler JM, Duncan LA, Chase RL (1986) The involvement of iron in lipid peroxidation: importance of ferric to ferrous rat in initiation. J Biol Chem 261:10282–10289.PubMedGoogle Scholar
  9. Canellakis ZN, Marsh LIL, Bondy PK (1989) Yale J Biol Med 62:481–491.PubMedGoogle Scholar
  10. Cohen G (1988) Oxygen radicals and Parkinson’s disease. In: Halliwell B (ed) Oxygen radicals and tissue injury. FASEB, Bethesda, pp 130–138.Google Scholar
  11. Cohen G, Heikkila RE, McNamee D (1974) The generation of hydrogen peroxide, Superoxide radical and hydroxyl radical by 6-hydroxy-dopamine dialuric acid and related cytotoxic agents. J Biol Chem 249:2447–2459.PubMedGoogle Scholar
  12. Dexter DT, Carter CJ, Well FR, Javoy-Agid F, Agid Y, Lee SN, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52:381–389.PubMedCrossRefGoogle Scholar
  13. Halliwell B (1989) Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 126:35–47.Google Scholar
  14. Halliwell B, Gutteridge JM (1986) Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 246:501–514.PubMedCrossRefGoogle Scholar
  15. Hayashi O (ed) (1989) Oxygen free radicals and medicine. Elsevier, Amsterdam Heby O (1981) Role of polyamines in the control of cell proliferation and differentiation. Differentiation 19:1–11.Google Scholar
  16. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334:345–348.PubMedCrossRefGoogle Scholar
  17. Iacopino AM, Christakos S (1990) Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 87:4078–4082.PubMedCrossRefGoogle Scholar
  18. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm 2(4):327–340.CrossRefGoogle Scholar
  19. Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H (1990) Normal mitochondrial genome in brain from patients with Parkinson’s disease and complex I defect. J Neurochem 55:1810–1812.PubMedCrossRefGoogle Scholar
  20. Markey S, Kopin I, Trevor A, Castagnoli N Jr (eds) (1986) MPTP: a neurotoxin producing a Parkinsonian syndrome. Academic Press, London.Google Scholar
  21. Orrenius S, McConkey DJ, Bellomo G, Pierluigi N (1989) Role of Ca2+ in toxic cell killing. TIPS 10:281–285.PubMedGoogle Scholar
  22. Pilas B, Sana T, Kalyanarman B, Swartz HM (1988) The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Rad Biol Med 4:285–293.PubMedCrossRefGoogle Scholar
  23. Riederer P, Sofic E, Rausch W, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52:515–521.PubMedCrossRefGoogle Scholar
  24. Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in the brains of Parkinsonian patients treated with 1-deprenyl. J Neurochem 46:1349–1356.CrossRefGoogle Scholar
  25. Russel DH (1980) Ornithine decarboxylase as a biological and pharmacological tool. Pharmacology 20:117–126.CrossRefGoogle Scholar
  26. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD (1989) A selective increase in particulate Superoxide dimutase activity in Parkinsonian substantia nigra. J Neurochem 53:692–698.PubMedCrossRefGoogle Scholar
  27. Seiler N (1985) Acetylpolyamines as substrates of amine oxidases. In: Mondovi B (ed) Structure and function of amine oxidases. CRC Press, Boca Raton, pp 21–37.Google Scholar
  28. Seiler N (1989) Metabolism and physiological roles of polyamines. In: Bacharach U, Keimer Y (eds) Physiology of polyamines. CRC Press, Boca Raton, pp 159–179.Google Scholar
  29. Seiler N, Al-Therib MJ (1974a) Putrescine catabolism in mammalian brain. Biochem J 144:29–35.PubMedGoogle Scholar
  30. Seiler N, Al-Therib MJ (1974b) AcetylCoA: 1,4-diaminobutane N-acetylpolyamines in vertebrate organs and subcellular distribution. Biochim Biophys Acta 354:206–212.PubMedCrossRefGoogle Scholar
  31. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J Neurochem (in press).Google Scholar
  32. Tetrud JW, Langston W (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245:519–522.PubMedCrossRefGoogle Scholar
  33. The Parkinson Study Group Datatop (1989) Selegiline and Parkinson’s disease. N Engl J Med 321:1364–1371.CrossRefGoogle Scholar
  34. Youdim MBH (1985) Brain iron metabolism: biochemical and behavioural aspects in relation to dopaminergic neurotransmission In: Lajtha A (ed) Handbook of neurochemistry, vol 10. Plenum, New York, pp 731–756.Google Scholar
  35. Youdim MBH (1990) Developmental neuropharmacological and biochemical aspects of iron-deficiency In: Dobbing J (ed) Brain behaviour and iron deficiency. Springer, Berlin Heidelberg New York.Google Scholar
  36. Youdim MBH, Ben-Shachar D, Pollard HB (1991) The effects of iron chelators and calcium antagonists on iron induced neuronal peroxidation. Br J Pharmacol (in press).Google Scholar
  37. Youdim MBH, Ben-Shachar D, Riederer P (1989) Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?. Acta Neurol Scand 126:47–54.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • M. B. H. Youdim
    • 1
  • D. Ben-Shachar
    • 1
  • P. Riederer
    • 2
  1. 1.Technion — Israel Institute of Technology, Faculty of MedicineDepartment of PharmacologyHaifaIsrael
  2. 2.Department of PsychiatryUniversity of WürzburgWürzburgFederal Republic of Germany

Personalised recommendations